resource-symbol

Insulin Treatment Satisfaction Questionnaire (ITSQ)

Novo Nordisk (Denmark)

Distributed by Mapi Research Trust

Distributed by Mapi Research Trust

default distrib
 

Basic description

Developed in 2004

Authors

Novo Nordisk (Denmark)

Copyright
ITSQ © Novo Nordisk, 2004, All rights reserved.
Objective
To measure insulin treatment satisfaction, applicable to a wide range of insulin therapies
Therapeutic area
  • Nutritional and Metabolic Diseases
  • Endocrine System Diseases
Therapeutic indication

Diabetes Mellitus

Type 1 - IDDM, Type 2 - NIDDM
Type of Clinical Outcome Assessment (COA)
  • PRO PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Anderson RT, Skovlund SE, Marrero D, Levine DW, Meadows K, Brod M, Balkrishnan R. Development and validation of the insulin treatment satisfaction questionnaire. Clin Ther. 2004 Apr;26(4):565-78 (abstract)


Contact and conditions of use

Authors

Novo Nordisk (Denmark)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Non-Commercial Users

If you do not receive specific funding for your study, you may download the questionnaire directly:

  1. Log in or Register for free
  2. Click the 'Online distribution' tab in the left menu bar and follow the instructions

Tutorials are available on our FAQs.

Commercial Users

All requests have to be submitted through our online request management:

  1. Log in or Register for free
  2. Submit your request (Tutorials are available on our FAQs)
  3. In order to accelerate the process, you may attach the User Agreement (even if not finalized) to your online request. Click the link below for the user agreement template.
  4. Our PROVIDE team will get back to you with the needed information in a timely manner

Access fees

ROYALTY FEES* Commercial users Cost per study 500 €
Cost per language 500 €
Funded academic research Cost per study Free
Cost per language Free
Not funded academic users Cost per study Free
Cost per language Free
DISTRIBUTION FEES* Commercial users Cost per study 700 €
Cost per language 300 €
Funded academic research Cost per study 300 €
Cost per language 50 €
Not funded academic users Cost per study Free
Cost per language Free

* Excluding VAT
Commercial users: Industry, CRO, any for-profit companies
Funded Academic research: Projects receiving funding from commerce, government, EU or registered charity. Funded academic research– sponsored by industry fits the “commercial users” category.
Not funded academic users, individual medical practice: Projects are not explicitly funded, but funding comes from overall departmental funds or from the University or individual funds

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Online distribution

For Non-Funded Academic Studies

The following licensing process is restricted to academic users:

  • Who do not receive specific funding for their study
  • Who intend to use the questionnaire in individual clinical practice or research study

Should you not correspond to this category of users, please send us a request.

Note: This site aims at providing you with the original version and existing translations of the questionnaire. However some modules/versions may not be downloadable in the language you need.

Login

To access this section, please complete a client account.

Languages

Original language(s)

  • English for the USA

Translations

The translations listed may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study. This list is subject to constant changes, therefore please check the status of translations with Mapi Research Trust / the developers / copyright holders / distributors.

ITSQ

Arabic for Israel
Bengali for India*
Bulgarian for Bulgaria
Chinese for Hong Kong
Chinese for Malaysia*
Chinese for Singapore
Chinese for Taiwan
Czech for Czech Republic
Danish for Denmark
Dutch for the Netherlands*
English for Australia*
English for Canada*
English for India*
English for the UK*
Finnish for Finland*
French for Canada*
French for France*
German for Germany*
German for Switzerland*
Greek for Greece*
Hebrew for Israel
Hindi for India*
Hungarian for Hungary*
Italian for Italy*
Japanese for Japan*
Kannada for India*
Korean for Korea*
Malay for Malaysia*
Malay for Singapore
Malayalam for India*
Mandarin for China*
Mandarin for Malaysia*
Marathi for India*
Norwegian for Norway
Polish for Poland*
Portuguese for Brazil*
Romanian for Romania*
Russian for Israel*
Russian for Russia
Slovak for Slovakia*
Slovenian for Slovenia
Spanish for Argentina*
Spanish for Colombia*
Spanish for Mexico*
Spanish for Peru*
Spanish for Spain*
Spanish for the USA*
Swedish for Sweden*
Tamil for India*
Telugu for India*
Turkish for Turkey
* Performed by Mapi

The author has selected Mapi as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi

Last update: February 2017
For additional information, please submit a request. More information in our FAQs.